All lobbying filings

AVENUE SOLUTIONS

Lobbying for GENENTECH USA, INC. · Biotechnology

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · California · House · Senate · $50,000.00 income · posted Apr 20, 2026

Official filing document

Bills named in this filing 3

HR 4299
Protecting Patient Access to Cancer and Complex Therapies Act
HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
HR 1672
Maintaining Investments in New Innovation Act

Lobbying activity 2

Medicare/Medicaid

Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Support for H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 1672, Maintaining Investments in New Innovation Act; Issues related to Senate Finance Dear Colleague process

Health Issues

Issues related to 340b drug pricing program; Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders and expiring Advanced Premium Tax Credits (APTC)

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.